论文部分内容阅读
目的观察奥扎格雷钠治疗急性脑梗死(ACI)的疗效和不良反应。方法 108例ACI分为治疗组(60例)和对照组(48例),治疗组静脉滴注奥扎格雷80 mg,1次/d;对照组静脉滴注维脑路通600 mg,1次/d,疗程均为14 d,观察两组患者治疗前后临床神经功能缺损程度评分,血流变学及血脂变化,进行自身比较和相互比较。结果治疗组总有效率为93.3%;明显高于对照组的73%(P<0.05)。治疗组全血高切粘度(HSR)、血浆粘度(HP)、红细胞聚集指数、红细胞压积(HCT)、甘油三酯(TG)比治疗前明显降低(P<0.01),并低于对照组(P<0.05),两组血小板计数(PLT)、血胆固醇(TC)与治疗前相比差异无统计学意义(均P>0.05),两组均无明显不良反应。结论奥扎格雷是治疗急性脑梗死(ACI)的有效药物,值得临床推广使用。
Objective To observe the efficacy and adverse reactions of ozagrel sodium in the treatment of acute cerebral infarction (ACI). Methods 108 cases of ACI were divided into treatment group (60 cases) and control group (48 cases). The treatment group was given intravenous injection of ozagrel 80 mg once daily, while the control group was given intravenous injection of Venoruton 600 mg once, / d, the course of treatment was 14 d, the clinical neurological deficit score, hemorheology and blood lipid changes were observed before and after treatment in both groups, compared with each other and compared with each other. Results The total effective rate was 93.3% in the treatment group, which was significantly higher than 73% in the control group (P <0.05). Compared with the control group, the high blood viscosity (HSR), plasma viscosity (HP), erythrocyte aggregation index, hematocrit (HCT) and triglyceride (TG) in the treatment group were significantly lower than those before treatment (P <0.01) (P <0.05). There was no significant difference in platelet count (PLT) and blood cholesterol (TC) between the two groups (all P> 0.05). There was no significant adverse reaction in both groups. Conclusion Ozagrel is an effective drug in the treatment of acute cerebral infarction (ACI), which is worthy of clinical promotion.